NIOSHTIC-2 Publications Search
Two dimensional electrophoretic protein profile associated with EMF inhibition of cytostatic effect of tamoxifen of MCF-7 cell growth.
Kanitz-MH; Afzal-SMJ; Liburdy-RP; Savage-RE
Proceedings of the Eighty-Ninth Annual Meeting of the American Association for Cancer Research, March 28 - April 1, 1998, New Orleans, Louisiana. Philadelphia, PA: American Association for Cancer Research, 1998 Mar-Apr; 39:334
Epidemiological studies suggest and increased risk of breast cancer is associated with exposure to electromagnetic fields (EMFs). Previous investigations have showed that a 12 mG, 60 Hz magnetic field significantly inhibits the cytostatic action of pharmacological doses of tamoxifen (10-7 M) on the growth of MCF-7 human breast cancer cells. Here we use high resolution two dimensional polyacrylamide gel electrophoresis (2D AGE) to investigate phenotypic biochemical alterations which may represent protein biomarkers of effect of exposure of drug-treated human breast cancer cells to an environmental-level magnetic field. Solubilized MCF-7 cell fractions (20 uG) from each treatment group (contol -2 mG field; control -12 mG field; tamoxifen -2 mG field; tamoxifen - 12 mG field) are subjected to 2D PAGE using the Anderson ISODALT method. Computer analysis and comparison of gel patterns across treatment groups were performed using PDQUEST software (BioRad Labs, CA). The protein alterations associated with the observed -12 mG blocking effect of tamoxifen inhibition are characterized with respect to Mr and pl. These studies may provide an understanding at the biochemical level of the EMF-induced reversal of tamoxifen's cell growth inhibition of human breast cancer cells and offer some insight into the putative role of EMF in human breast cancer risk.
Cell-growth; Epidemiology; Electromagnetic-fields; Risk-factors; Risk-analysis; Exposure-levels; Breast-cancer; Cancer; Biomarkers
Abstract; Conference/Symposia Proceedings
Proceedings of the Eighty-Ninth Annual Meeting of the American Association for Cancer Research, March 28 - April 1, 1998, New Orleans, Louisiana
OH; CA; PA; LA
Page last reviewed: September 2, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division